Sanofi (NASDAQ:SNY) Shares Sold by National Bank of Canada FI

National Bank of Canada FI decreased its holdings in Sanofi (NASDAQ:SNY) by 16.9% in the third quarter, Holdings Channel reports. The fund owned 297,845 shares of the company’s stock after selling 60,595 shares during the period. National Bank of Canada FI’s holdings in Sanofi were worth $17,165,000 at the end of the most recent reporting period.

A number of other institutional investors have also bought and sold shares of SNY. Northwest Investment Counselors LLC acquired a new stake in shares of Sanofi in the third quarter valued at approximately $29,000. POM Investment Strategies LLC acquired a new stake in shares of Sanofi in the 2nd quarter worth $25,000. Concord Wealth Partners raised its holdings in shares of Sanofi by 157.8% during the 3rd quarter. Concord Wealth Partners now owns 593 shares of the company’s stock worth $34,000 after acquiring an additional 363 shares during the period. Arrow Financial Corp acquired a new position in shares of Sanofi during the 2nd quarter valued at about $35,000. Finally, Fortitude Family Office LLC grew its holdings in shares of Sanofi by 708.6% in the third quarter. Fortitude Family Office LLC now owns 752 shares of the company’s stock valued at $43,000 after purchasing an additional 659 shares during the period. 10.04% of the stock is owned by hedge funds and other institutional investors.

Sanofi Price Performance

SNY stock opened at $48.43 on Tuesday. The business has a 50 day moving average price of $51.90 and a 200 day moving average price of $52.12. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17. The stock has a market cap of $122.91 billion, a price-to-earnings ratio of 24.71, a PEG ratio of 1.23 and a beta of 0.58. Sanofi has a fifty-two week low of $45.22 and a fifty-two week high of $58.97.

Sanofi (NASDAQ:SNY) last issued its earnings results on Friday, October 25th. The company reported $1.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.22 by $1.35. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The business had revenue of $13.44 billion during the quarter, compared to analysts’ expectations of $16.59 billion. During the same quarter in the prior year, the business posted $2.55 EPS. The company’s revenue for the quarter was up 12.3% on a year-over-year basis. Equities research analysts anticipate that Sanofi will post 4.27 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the stock. Citigroup upgraded shares of Sanofi to a “strong-buy” rating in a report on Tuesday, September 17th. StockNews.com lowered Sanofi from a “buy” rating to a “hold” rating in a research note on Friday. Two research analysts have rated the stock with a hold rating, one has given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $57.50.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.